Multimodal Clinical Decision Support for Post-Acute Care

This article discusses how multimodal clinical decision support, using speech biomarkers and visual data, enhances patient care in post-acute care (PAC) settings. Scienza Health's digitalhumanOS platform analyzes over 2,500 speech biomarkers to provide rapid insights into a patient's cognitive and mental well-being, and is 510(k) cleared and HIPAA compliant. GIA is the screening tool that uses the digitalhumanOS platform.

How does multimodal data enhance post-acute care assessments?

Multimodal clinical decision support enhances assessments by integrating multiple sources of information, primarily speech biomarkers and visual data, offering a more complete understanding of a patient's condition. By analyzing subtle variations in speech patterns and visual cues, the digitalhumanOS platform can detect early indicators of cognitive decline and depression. This integration contributes to a more accurate screening process, leading to better-informed clinical decisions and improved patient outcomes. GIA screens; she does not diagnose. A clinician reviews and approves results before they enter the clinical record.

How do speech biomarkers unlock insights into patient health?

Speech biomarkers unlock insights into patient health by providing valuable information about a patient's mental and cognitive state through the analysis of speech patterns. The Scienza Health platform analyzes over 2,500 speech biomarkers, including acoustic features, linguistic patterns, and vocal dynamics, to reveal subtle changes in cognitive function, emotional state, and neurological health. For example, changes in speech rate can indicate cognitive impairment or depression. Our Parkinson's screening, for example, has an AUC of 0.97.

How does multimodal support improve screening accuracy and efficiency?

Multimodal clinical decision support improves screening accuracy and efficiency by automating data collection and analysis, providing rapid results. The digitalhumanOS platform delivers objective results in under 60 seconds, allowing clinicians to screen more patients in less time. The platform has high accuracy rates, such as 81.6% for depression screening, 77.5% for anxiety, and 80.0% for PTSD. The integration with Samsung Health Grade Galaxy devices with Samsung Knox ensures data security and patient privacy, with GIA speaking 92 languages.

How does the platform integrate with EHR systems?

The multimodal clinical decision support platform directly integrates with existing electronic health record (EHR) systems to maximize its impact. The Scienza Health platform integrates with leading EHR systems, including PointClickCare, Epic, Cerner, and MatrixCare, allowing for the direct flow of data and ensuring clinicians have access to up-to-date information. This integration also enables automatic documentation of screening results, reducing the burden on clinicians. ADLs and IADLs can be administered by GIA, with results written back to the EHR. CPT codes 96127, 96116, and 99309 are supported.

How does the platform address undiagnosed conditions?

The platform addresses undiagnosed conditions in post-acute care by providing a more sensitive and objective screening tool. Many conditions like tardive dyskinesia (TD) and mild cognitive impairment (MCI) often go undiagnosed, with 98.5% of TD cases and 92% of the 12.3M Americans with MCI being unaware of their condition. By detecting early indicators of TD, MCI, and other conditions, the digitalhumanOS platform helps clinicians identify patients who may benefit from further evaluation and treatment. CMS F-Tag 605 addresses unnecessary drugs; our platform can assist in reducing reliance on them.

What does the digitalhumanOS Platform offer?

The Scienza Health digitalhumanOS platform offers a complete approach for multimodal clinical decision support in post-acute care. The platform analyzes over 2,500 speech biomarkers, integrates with existing EHR systems, and has high accuracy rates, improving patient care and outcomes. Clinicians can screen for 46 conditions in under 5 minutes and receive results in 60 seconds. The platform has been used with 12.3M patients and 27B clinical events, demonstrating its scalability and reliability.

Conclusion

Multimodal clinical decision support is transforming post-acute care by providing clinicians with the tools they need to make better-informed decisions and improve patient outcomes. The Scienza Health digitalhumanOS platform, with its ability to analyze over 2,500 speech biomarkers and integrate with existing EHR systems, offers a complete approach for screening a wide range of conditions. By using the power of multimodal data, clinicians can detect early indicators of cognitive decline, depression, and other conditions, leading to more timely and effective interventions. If you're interested in exploring how the digitalhumanOS platform can benefit your organization, request a demo today.